Verastem Inc (VSTM) Stock AnalysisVSTMVerastem Inc

Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Verastem Inc (VSTM) appears to be a good buy right now, trading at $10.04 with a recent RSI of 74.014 indicating strong momentum. The company has raised its price target to $22, suggesting a potential upside of 118% from the current price. Additionally, the stock has shown a significant 5-day change of +16.07%, indicating positive short-term momentum. However, the main risk is the negative net income of -34,673,000 USD in Q2 2026, which highlights ongoing financial challenges.

5 analysts cover VSTM: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 15.60.